
Moderna, Inc. ownership: holders and insider trading
$223.37−3.45%Close 13 Nov 2026 · Market value $87.52B
As filed, its directors and officers own 10.8% of the shares (proxy statement, 9 Mar 2026); 777 institutional managers reported holding 78.9% at 30 Jun 2026. Over the last twelve months, insiders sold $81.65M of shares on the open market, $80.51M of it under 10b5-1 plans set in advance, and bought none.
From the company's proxy statement, each holder's latest Schedule 13D or 13G, the institutional managers' quarterly 13F reports and the insiders' Form 4 filings. A percentage is shown as filed; one marked * is worked out here from the shares outstanding.
Largest holders
| Holder | Type | Shares | Of the company | Source | As of |
|---|
| FMR LLC | Holder | 58.9M | 14.8% | Schedule 13G | 30 Sep 2026 |
|---|
| Fidelity (FMR) | Institution | 51.9M | 12.84%* | Form 13F | 30 Jun 2026 |
|---|
| The Vanguard Group | Holder | 42.0M | 10.39%* | Form 13F | 30 Jun 2026 |
|---|
| Stéphane Bancel · Chief Executive Officer and Director | Insider | 30.7M | 7.6% | Proxy statement | 9 Mar 2026 |
|---|
| BlackRock, Inc. | Holder | 30.6M | 7.57%* | Form 13F | 30 Jun 2026 |
|---|
| Vanguard Capital Management | Holder | 25.9M | 6.53% | Schedule 13G | 31 Mar 2026 |
|---|
| Capital Group | Institution | 22.3M | 5.51%* | Form 13F | 30 Jun 2026 |
|---|
| Capital World Investors | Holder | 22.3M | 5.6% | Schedule 13G | 30 Jun 2026 |
|---|
| Baillie Gifford & Co | Holder | 18.2M | 4.51%* | Form 13F | 30 Jun 2026 |
|---|
| State Street | Institution | 15.7M | 3.89%* | Form 13F | 30 Jun 2026 |
|---|
| Geode Capital Management | Institution | 9.7M | 2.40%* | Form 13F | 30 Jun 2026 |
|---|
| Morgan Stanley | Institution | 9.5M | 2.36%* | Form 13F | 30 Jun 2026 |
|---|
| Theleme Partners LLP | Institution | 8.1M | 1.99%* | Form 13F | 30 Jun 2026 |
|---|
| Two Sigma Investments, LP | Institution | 7.2M | 1.78%* | Form 13F | 30 Jun 2026 |
|---|
| Noubar B. Afeyan, Ph.D. · Chairman | Insider | 7.1M | 1.8% | Proxy statement | 9 Mar 2026 |
|---|
| UBS | Institution | 6.0M | 1.48%* | Form 13F | 30 Jun 2026 |
|---|
| Invesco | Institution | 5.8M | 1.43%* | Form 13F | 30 Jun 2026 |
|---|
| T. Rowe Price | Institution | 5.6M | 1.38%* | Form 13F | 30 Jun 2026 |
|---|
| Stephen Hoge, M.D. · President | Insider | 5.2M | 1.3% | Proxy statement | 9 Mar 2026 |
|---|
| Charles Schwab | Institution | 4.8M | 1.20%* | Form 13F | 30 Jun 2026 |
|---|
Insider transactions latest 25
Form 4 filings since 16 Nov 2024: purchases and sales, grants, option exercises and shares withheld for tax. Gifts and other transfers are left out.
MRNA in the terminal
Holders over eight quarters by family, every Form 4 and Form 144 back two years, and alerts on insider buying.